| Registered Number | 99854 |
|---|---|
| Registered Address |
22 Grenville Street St Helier Jersey JE4 8PX |
| Head Office |
5 Riverwalk Citywest Business Campus Dublin 24 Republic of Ireland JE4 8PX |
| Phone Number | +353 1 4297700 |
| Fax Number | |
| Website | http://www.shire.com |
| Activities | Develops manufactures and markets pharmaceuticals |
| Country of Register | JE |
| Currency | GBX |
| Short Name | SHIRE |
| First Day Traded | 23/05/2008 |
| Industrial Sector | Pharmaceuticals |
| Number of shares | 562m |
| Matthew Emmens | Chairman |
|---|---|
| Angus Russell | Chief Executive Officer |
| Anne Minto | Non Executive Director |
| Graham Hetherington | Financial Director |
| BlackRock Investment Management (UK) Ltd. | 5.93% |
|---|---|
| Legal & General Investment Management Ltd. | 3.96% |
| Director | Date | Buy/Sell | Quantity | Price |
|---|---|---|---|---|
You need to be a Selfrade customer to access this data. |
||||
| AR 2006 | AR 2007 | AR 2008 | AR 2009 | AR 2010 | |
| Fiscal Year End | 31/12/2006 | 31/12/2007 | 31/12/2008 | 31/12/2009 | 31/12/2010 |
| Duration (months) | 12 | 12 | 12 | 12 | 12 |
| Accounting Format | IFRS | IFRS | IFRS | IFRS | IFRS |
| Sales/Revenue | 975.94 | 1,217.40 | 1,648.48 | 1,927.31 | 2,248.23 |
| Cost of Goods Sold (COGS) incl. D&A | 201.00 | 252.59 | 291.38 | 336.35 | 386.61 |
| COGS excluding D&A | 134.78 | 153.11 | 177.98 | 176.03 | 221.12 |
| Depreciation & Amortization Expense | 66.22 | 99.49 | 113.40 | 160.33 | 165.49 |
| Depreciation | 21.95 | 25.28 | 40.91 | 63.25 | 77.21 |
| Amortization of Intangibles | 44.27 | 74.20 | 69.76 | 97.08 | 88.28 |
| Amortization of Deferred Charges | 0 | 0 | 2.73 | 0 | 0 |
| Gross Income | 774.94 | 964.81 | 1,357.10 | 1,590.96 | 1,861.62 |
| Selling, General & Administrative Expense | 608.16 | 786.02 | 1,083.88 | 1,178.61 | 1,330.57 |
| Research & Development | 160.69 | 259.24 | 430.75 | 410.04 | 428.45 |
| Other Selling, General & Administrative | 447.47 | 526.78 | 653.13 | 768.57 | 902.12 |
| Other Operating Expense | 0 | 0 | 0 | 0 | 0 |
| Non Operating Income/Expense | 40.47 | 54.42 | -22.64 | 43.45 | 16.78 |
| Non-Operating Interest Income | 27.43 | 25.28 | 13.91 | 1.22 | 1.55 |
| Equity in Affiliates (Pretax) | 0 | 0 | 0 | 0 | 0 |
| EBIT | 0 | 0 | 0 | 0 | 0 |
| Unusual Expense | 152.76 | 197.18 | 91.42 | 19.48 | 28.37 |
| EBIT after Unusual Expense | 0 | -197.18 | -91.42 | -19.48 | -28.37 |
| Interest Expense | 14.67 | 46.52 | 28.20 | 25.50 | 22.73 |
| Gross Interest Expense | 14.67 | 46.52 | 28.20 | 25.50 | 22.73 |
| Interest Capitalized | 0 | 0 | 0 | 0 | 0 |
| Pretax Income | 67.25 | 14.79 | 144.87 | 412.03 | 498.28 |
| Income Tax | 61.93 | -25.48 | 53.45 | 88.75 | 118.33 |
| Income Tax - Current Domestic | 121.14 | 44.02 | 0.16 | 0 | 0 |
| Income Tax - Current Foreign | 0 | 0 | 4.15 | 0 | 0 |
| Income Tax - Deferred Domestic | -59.21 | -69.51 | 16.25 | 0 | 0 |
| Income Tax - Deferred Foreign | 0 | 0 | 32.89 | 0 | 0 |
| Income Tax Credits | 0 | 0 | 0 | 0 | 0 |
| Minority Interest Expense | 0 | 0 | -1.96 | -0.13 | 0 |
| Equity in Affiliates | 3.15 | 0.90 | 1.31 | -0.45 | 0.91 |
| Other After Tax Income (Expense) | 0 | 0 | 0 | 0 | 0 |
| Net Income | 8.47 | 41.17 | 94.69 | 322.96 | 380.85 |
| Extraordinaries & Discontinued Operations | 22.06 | 0 | -9.60 | -7.95 | 0 |
| Extra Items & Gain/Loss Sale Of Assets | 22.06 | 0 | 0 | 0 | 0 |
| Cumulative Effect - Accounting Chg | 0 | 0 | 0 | 0 | 0 |
| Discontinued Operations | 0 | 0 | -9.60 | -7.95 | 0 |
| Net Income After Extraordinaries | 30.53 | 41.17 | 85.09 | 315.01 | 380.85 |
| Preferred Dividends | 0 | 0 | 0 | 0 | 0 |
| Net Income available to Common | 8.47 | 41.17 | 94.69 | 322.96 | 380.85 |
| Operational EPS | 26.99 | 32.64 | 29.10 | 61.42 | 71.56 |
| EPS (basic) | 1.68 | 7.65 | 15.71 | 58.25 | 69.76 |
| EPS (diluted) | 5.99 | 7.50 | 17.36 | 58.93 | 68.19 |
| EBITDA | 233.00 | 278.28 | 386.62 | 572.68 | 696.54 |
| EBIT | 0 | 0 | 0 | 0 | 0 |
| +Depreciation & Amortization Expense | 66.22 | 99.49 | 113.40 | 160.33 | 165.49 |